Skip to main content
Erschienen in: Clinical Rheumatology 4/2008

01.04.2008 | Case Report

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

verfasst von: Maria G. Tektonidou, Fotini N. Skopouli

Erschienen in: Clinical Rheumatology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Tumor necrosis factor (TNF) is a proinflammatory cytokine that plays a key role in the pathogenesis of autoimmune diseases and is an important constituent of the human immune response to infection. We report the case of a 45-year-old man with psoriatic arthritis, receiving treatment with infliximab, who presented with high-grade fever, rigor, splenomegaly, acute reactive proteins, and pancytopenia. The diagnosis of visceral leishmaniasis was established. The patient reported that his dog died from Leishmania infection 5 years ago, while he was living in an area endemic for Leishmania. The use of anti-TNF biologic agent in this patient might result in new infection or reactivation of a latent infection with Leishmania, 5 years after the exposure. A detailed current and past medical history should be obtained of every patient candidate for treatment with biologic agents, and a close monitoring is needed for serious opportunistic infections, including visceral leishmaniasis.
Literatur
1.
Zurück zum Zitat Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602–610PubMedCrossRef Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602–610PubMedCrossRef
2.
Zurück zum Zitat Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376PubMedCrossRef Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376PubMedCrossRef
3.
Zurück zum Zitat Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J (2005) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 23:891–892PubMed Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J (2005) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 23:891–892PubMed
4.
Zurück zum Zitat Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C (2006) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 45:1446–1448CrossRef Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C (2006) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 45:1446–1448CrossRef
5.
Zurück zum Zitat Bagalas V, Kioumis I, Argyropoulou P, Patakas D (2007) Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 26:1344–1345PubMedCrossRef Bagalas V, Kioumis I, Argyropoulou P, Patakas D (2007) Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 26:1344–1345PubMedCrossRef
6.
Zurück zum Zitat Jewell AP, Giles FJ (1996) Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia. Leuk Lymphoma 21:347–349PubMedCrossRef Jewell AP, Giles FJ (1996) Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia. Leuk Lymphoma 21:347–349PubMedCrossRef
7.
Zurück zum Zitat Czechowicz RT, Millard TP, Smith HR, Ashton RE, Lucas SB, Hay RJ (1999) Reactivation of cutaneous leishmaniasis after surgery. Br J Dermatol 141:1113–1116PubMedCrossRef Czechowicz RT, Millard TP, Smith HR, Ashton RE, Lucas SB, Hay RJ (1999) Reactivation of cutaneous leishmaniasis after surgery. Br J Dermatol 141:1113–1116PubMedCrossRef
8.
Zurück zum Zitat Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW (1994) Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 153:768–775PubMed Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW (1994) Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 153:768–775PubMed
9.
Zurück zum Zitat Titus RG, Sherry B, Cerami A (1989) Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 170:2097–2104PubMedCrossRef Titus RG, Sherry B, Cerami A (1989) Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 170:2097–2104PubMedCrossRef
Metadaten
Titel
Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?
verfasst von
Maria G. Tektonidou
Fotini N. Skopouli
Publikationsdatum
01.04.2008
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 4/2008
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0775-y

Weitere Artikel der Ausgabe 4/2008

Clinical Rheumatology 4/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.